Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
  Allergy & asthma
  Biotechnology
  Communicable diseases
  Drugs & drug processes
  Genetic engineering
  Genomics
  Health & ageing
  Health & poverty
  Health & special needs
  Health systems & management
  Major diseases
  Medical research
  Molecular biology
  Neuroscience
  Public health
  Rare & orphan diseases
  Other
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Brazil
  Bulgaria
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Finland
  France
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lithuania
  Luxembourg
  Macedonia - former Yugoslav Republic
  Malta
  Mexico
  Montenegro
  Morocco
  Namibia
  Netherlands
  Nigeria
  Norway
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tunisia
  Turkey
  Ukraine
  United Kingdom
  United States


   Health & life sciences

Last Update: 28-02-2011  
Related category(ies):
Health & life sciences  |  Research policy

 

Add to PDF "basket"

Scientists develop innovative technology to fight cancer

EU-funded researchers continue the good fight against cancer. A Dutch team has succeeded in boosting chemotherapy dosage to tumours with the possibility of easing harmful side effects by combining magnetic resonance imaging (MRI) and ultrasound. Their research is funded in part by the SONODRUGS ('Image-controlled ultrasound-induced drug delivery') project, which is backed with almost EUR 10.8 million under the Nanosciences, Nanotechnologies, Materials and new Production Technologies (NMP) Theme of the EU's Seventh Framework Programme (FP7).

Cancer cell © Shutterstock
Cancer cell
©  Shutterstock

Eindhoven University of Technology collaborated with Philips Electronics to create sophisticated technology with the potential to help patients in need. The team performed a demonstration of this technique for the first time ever in a pre-clinical, proof-of-concept study.

Around 50% of patients diagnosed with cancer undergo chemotherapy to treat their illness. Chemotherapy drugs flow through the bloodstream, damaging rapidly dividing cells like cancer cells. But in their quest to fight disease, chemotherapy drugs know no boundaries and end up attacking normal, healthy dividing cells found in various parts of the body including bone marrow, hair and mucosae. Patients then face a number of side effects, such as neutropaenia, a lower white blood cell count, and anaemia, a lower red blood cell count, as well as bleeding.

Some researchers say chemotherapy is complex in that the drugs are spread everywhere in the body and are not absorbed evenly; some regions fail to get the dosage they need.

Headed by Eindhoven's Holger Grüll, the team created a delivery method to tackle this problem. An MRI scan would initially be performed on cancer patients; this would help doctors localise the site and size of the tumour.

Liposomes, small temperature-sensitive particles containing an MRI contrast agent and a chemotherapy drug, are injected into the patients and move through the bloodstream until they reach their target, the tumour. The contrast agent moves along with the drug allowing it to follow the path of the drug inside the body and localise when it reaches the tumour and surrounding tissue. At this point a high-intensity focused ultrasound (HIFU) beam is used to burst the liposomes and release the drug at the site of the tumour.

For the purposes of their study, the researchers assessed the uptake of the anti-cancer agent doxorubicin in rats. They found that uptake was between two and five times higher in induced tumours versus regular chemotherapy delivery.

'In some tumours, you have a centre part that is no longer supplied with blood, and so the chemotherapy cannot reach that part and cannot kill it,' said Matthew Harris from Philips Research.

The team said the prototype system is based on a Sonalleve 3-Tesla MRI-HIFU scanner, which is used to treat uterine fibroids — painful benign tumours formed from the muscular layer in a woman's uterus. The MRI scanner combined with high-intensity ultrasounds pinpoints and removes the fibroids via ablation, the removal of unwanted cells.

This proof of concept appeared in the Journal of Controlled Release in February 2011.


Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Eindhoven University of Technology
SONODRUGS





  Top   Research Information Center